National Health (Highly specialised drugs program for hospitals) Special Arrangement Amendment Instrument 2014 (No. 7) (PB 55 of 2014)

Link to law: https://www.comlaw.gov.au/Details/F2014L01065

Subscribe to a Global-Regulation Premium Membership Today!

Key Benefits:

Subscribe Now
 
PB 55 of 2014
National Health (Highly specialised drugs program for hospitals) Special Arrangement Amendment Instrument 2014 (No. 7)
 
National Health Act 1953
___________________________________________________________________________
 
 
I, KIM BESSELL, Assistant Secretary, Pharmaceutical Access Branch, Pharmaceutical Benefits Division, Department of Health, delegate of the Minister for Health, make this Amendment Instrument under subsections 100(1) and 100(2) of the National Health Act 1953.
Dated  24 July 2014
 
 
 
 
 
 
 
 
 
 
 
 
 
 
KIM BESSELL
Assistant Secretary
Pharmaceutical Access Branch
Pharmaceutical Benefits Division
Department of Health
___________________________________________________________________________
 
 
1       Name of Instrument
 
(1)                This Instrument is the National Health (Highly specialised drugs program for hospitals) Special Arrangement Amendment Instrument 2014 (No.7).
 
(2)                This Instrument may also be cited as PB 55 of 2014.
 
2              Commencement
This Instrument commences on 1 August 2014.
3              Amendments to PB 116 of 2010
Schedule 1 amends the National Health (Highly specialised drugs program for hospitals) Special Arrangement 2010 (PB 116 of 2010).
 
 
Schedule 1       Amendments
[1]           Schedule 1, after entry for Epoprostenol in the form Powder for I.V. infusion, 500 micrograms (as sodium) infusion administration set
insert in the columns in the order indicated:
 
Powder for I.V. infusion 500 micrograms (as sodium)
Injection
Veletri
AT
EMP
C3167 C4013 C4014
 
See Note 1
See Note 2
D
 
[2]           Schedule 1, after entry for Epoprostenol in the form Powder for I.V. infusion, 1.5 mg (as sodium) infusion administration set
insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:
 
Powder for I.V. infusion 1.5 mg (as sodium)
Injection
Veletri
AT
EMP
C3167 C4013 C4014
 
See Note 1
See Note 2
D
 
[3]            Schedule 1, entry for Omalizumab
Omalizumab
Injection 75 mg in 0.5 mL single dose pre-filled syringe
Injection
Xolair
NV
EMP
C3740 C3742 C3822
 
See Note 1
See Note 2
D

 
Injection 150 mg in 1 mL single dose pre-filled syringe
Injection
Xolair
NV
EMP
C3740 C3742 C3822
 
See Note 1
See Note 2
D

 
Powder for Injection 150 mg with Diluent
Injection
Xolair
NV
EMP
C3740 C3742 C3822
 
See Note 1
See Note 2
D

Substitute:
 
[4]           Schedule 1, entry for Sildenafil
 
 
 
APO-Sildenafil PHT
TX
EMP
C3174 C3175 C4017 C4018
 
See Note 1
See Note 2
D
(a)   insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:
 
(b)   insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:
 
 
 
Sildenafil Sandoz PHT 20
SZ
EMP
C3174 C3175 C4017 C4018
 
See Note 1
See Note 2
D
 
[5]           Schedule 1, entry for Tacrolimus in the form Capsule 0.5 mg
insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:
 
 
 
Pharmacor Tacrolimus 0.5
CR
EMP
C1654 C3328
 
200
5
C
 
[6]           Schedule 1, entry for Tacrolimus in the form Capsule 1 mg
insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:
 
 
 
Pharmacor Tacrolimus 1
CR
EMP
C1654 C3328
 
200
5
C
 
[7]           Schedule 1, entry for Tacrolimus in the form Capsule 5 mg
insert in the columns in the order indicated, and in alphabetical order for the column headed “Brand”:
 
 
 
Pharmacor Tacrolimus 5
CR
EMP
C1654 C3328
 
100
5
C